Sandoz Group AGSDZXF 18 EBIT per Share is $3.27 as of Dec. 2025. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Sandoz Group AG ranks worse than 63.46% on this metric.
Sandoz Group AG's EBIT per Share for the
six
months ended in Dec. 2025 was $1.86.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $3.27.
During the past 12 months, the average EBIT per Share Growth Rate of Sandoz Group AG was 312.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -1.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sandoz Group AG's EBIT per Share or its related term are showing as below:
SDZXF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -1 Med: -1 Max: -1
Current: -1
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Sandoz Group AG was -1.00% per year. The lowest was -1.00% per year. And the median was -1.00% per year.
SDZXF's 3-Year EBIT Growth Rate is ranked worse than 63.46% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs SDZXF: -1.00
Sandoz Group AG (OTCPK:SDZXF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sandoz Group AG EBIT per Share Related Terms
Sandoz Group AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (SDZXF) has a EBIT per Share of $3.27 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sandoz Group AG and its competitors. According to the industry distribution chart, Sandoz Group AG ranks #514 out of 810 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is Sandoz Group AG's EBIT per Share too high?
Sandoz Group AG's current EBIT per Share is $3.27. The Drug Manufacturers industry median EBIT per Share is 7.65. Sandoz Group AG's value of $3.27 is 57.3% below this industry median. Based on the distribution chart, Sandoz Group AG ranks #514 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #514 out of 810 companies for EBIT per Share. This places Sandoz Group AG in the lower half of its industry. The industry median EBIT per Share is 7.65. Sandoz Group AG's value of $3.27 is 57.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current EBIT per Share of $3.27 is 57.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current EBIT per Share is $3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current EBIT per Share of $3.27. The current EBIT per Share is $3.27 and 57.3% below the Drug Manufacturers industry median of 7.65. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current EBIT per Share is $3.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score
Get the complete analysis for SDZXF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 